Cutia Therapeutics (HKG:2487) said a post-hoc analysis of its Phase 3 clinical trial for CU-10201, a topical 4% minocycline foam for moderate to severe facial acne vulgaris, has been accepted for oral presentation at the 20th China Dermatologist Association Annual Meeting, according to a Monday bourse filing.

The analysis found early efficacy, with significant improvement in inflammatory lesions within the first week of treatment, and further gains in the second week, the company said.